FibroGen Announces Topline Data from Phase 3 LELANTOS-1 Study
This morning, FibroGen announced topline data from the Phase 3 LELANTOS-1 study of pamrevlumab, their investigational monoclonal antibody, for non-ambulatory patients with Duchenne muscular dystrophy. Although generally safe and well tolerated, pamrevlumab did not…Learn More